# Blue Cross and Blue Shield of Kansas

Medical Pharmacy Implementation Prior Authorization Program Provider Communication and Education

> Presented by: Tiffany Morris Title: Senior Provider Relations Manager



## Program Overview

2

4

(1)

## **Review Process**

3 Provider Portal

## Resources

# **Program Overview**

Effective **August 15<sup>th</sup> 2025, Blue Cross and Blue Shield of Kansas** will be implementing a change in how certain specialty drugs that fall under the medical benefit are managed.

This new program will be administered by the **Medical Pharmacy Solutions team at Prime Therapeutics (Prime)**. Prime will be responsible for reviewing and approving these drugs.


Beginning **August 7<sup>th</sup> 2025**, providers may begin contacting Prime to obtain prior authorizations for members who will receive treatment/drugs within the scope of this program on or after **August 15<sup>th</sup> 2025**.

For providers currently requesting medical benefit drug reviews with the Prime Therapeutics Pharmacy Benefit Team via CoverMyMeds and/or fax, this will represent a change in workflow. Providers will begin submitting medical benefit drug reviews for the in-scope drugs to Prime's Medical Pharmacy Solutions team by navigating to GatewayPA.com, or via phone at 800-424-1713

#### **Places of Service**



Prior authorization is required by Prime when the drugs are administered by practitioners in the following places of service (POS)



The program will apply to members enrolled in the following plans:

Commercial/Exchange Members



HCPCS	Brand Name		HCPCS	Brand Name		HCPCS	Brand Name	е	HCPCS	Brand Name	
Q2055	Abecma		J9036	bendamustine (Baxte	er)	J1743	Elaprase		J0223	Givlaari	
J9264	Abraxane		J9034	Bendeka		J3060	Elelyso		J0257	Glassia	
J3262	Actemra IV		J9034	BeneFIX		J2508	Elfabrio		J1447	Granix	
J0801	Acthar_HP		J0490	Benlysta IV		J7205	Eloctate		J0599	Haegarda	
J0791	Adakveo		J0179	Beovu		J1323	Elrexfio		J9179	Halaven	
J9042	Adcetris		J0597	Berinert		J9269	Elzonris		J7170	Hemlibra	
J9029	Adstiladrin		Q5139	Bkemv		J7799 (NOC)	Empaveli		J7190	Hemofil M	
J7192	Advate		J9039	Blincyto		J9358	Enhertu		J9355	Herceptin	
J7207	Adynovate		Q2054	Breyanzi		J1302	Enjaymo		J9356	Herceptin Hylecta	
J7171	Adzynma		J2329	Briumvi		J3590	Enspryng		Q5146	Hercessi	
J7210	Afstyla		Q5124	Byooviz		J3380	Entyvio		Q5113	Herzuma	
J3590	Ahzantive		J9064	cabazitaxel (Sandoz)		J3590	Enzeevu		J7187	Humate-P	
J1454	Akynzeo IV		Q2056	Carvykti		J9321	Epkinly		J7202	Idelvion*	
J1931	Aldurazyme		J1786	Cerezyme		J3590	Epysqli		J0638	Ilaris	
J7186	Alphanate		Q5128	Cimerli		J9055	Erbitux		J3245	Ilumya	
J7193	Alphanine SD		J0717	Cimzia		J7204	Esperoct		J9026	Imdelltra	
J7201	Alprolix		J2786	Cinqair		J3111	Evenity		J9173	Imfinzi	
J7214	Altuviiio		J0598	Cinryze		J1305	Evkeeza		J9347	Imjudo	
Q5126	Alymsys		J7175	Coagadex		J0178	Eylea		J3590	Imuldosa IV	
J9999	Amtagvi		J9286	Columvi		J0177	Eylea HD		J3590	Imuldosa SQ	
J0225	Amvuttra		J7180	Corifact		J0180	Fabrazyme		J1745	Infliximab unbrande	ed 🔺 🗖
J9028	Anktiva		J0802	Cortrophin		J0517	Fasenra		J9198	Infugem	
J0256	Aralast NP		J3247	Cosentyx IV		J7198	Feiba NF/VF		J1439	Injectafer	
J0881	Aranesp		J0584	Crysvita		J1744	Firazyr		J9319	Istodax	
J9035	Avastin		J9308	Cyramza		J0641	Fusilev		J7213	Ixinity	
J9999	Avzivi		J9348	Danyelza		J9331	Fyarro		J2782	Izervay	
J9023	Bavencio		J9145	Darzalex		Q5130	Fylnetra		J9281	Jelmyto	
J9036	Belrapzo		J9144	Darzalex Faspro		J9210	Gamifant		J9272	Jemperli	
J9036	bendamustine (Ap	ootex)	J9063	Elahere		J9301	Gazyva		J9043	Jevtana	

The above list consist of all drugs that are in scope for the PA Program. The drugs that were previously reviewed by the Prime MDR program and will transition to MPS Prime for prior authorization are represented with a "\Left". The drugs that are in scope for State of Kansas Employee Health Plan are represented with a "\Left".

Other drugs may require preauthorization through Blue Cross and the above list is subject to change. Please visit <a href="https://gatewaypa.com/policydisplay/54">https://gatewaypa.com/policydisplay/54</a> for current list of in scope 7 medications.

HCPCS	Brand Nan	ne	HCPCS	Brand Name		HCPCS	Brand Name		HCPCS	Brand Nam	le	HCPCS	Brand Name	HCPCS	Brand Name	
J7208	Jivi		J7193	Mononine		J9264	paclitaxel albumin-l	oound	J3490	Rivfloza		J0593 (only if not self-admin)	Takhzyro 🔺	J3385	Vpriv	
Q5136	Jubbonti		J1458	Naglazyme		J9177	Padcev		J7200	Rixubis		J3055	Talvey	J3032	Vyepti	
J9354	Kadcyla		J2506	Neulasta		J3590	Pavblu		J1449	Rolvedon		Q2053	Tecartus	J9999	Vyloy	
J1290	Kalbitor		J1442	Neupogen		J9306	Perjeta		J9318	romidepsin		J9999	Tecelra	J9332	Vyvgart	
J2840	Kanuma ,		J0219	Nexviazyme		J9316	Phesgo		J0596	Ruconest		J9022	Tecentriq	J9334	Vyvgart Hytru	ıl <u> </u>
J9271	Keytruda		J3590	Niktimvo		J1307	Piasky		J9061	Rybrevant		J9999	Tecentriq Hybreza	Q5138	Wezlana IV	
J0642	Khapzory		J7182	Novoeight		J9309	Polivy		J9021	Rylaze		J9380	Tecvayli	Q5137	Wezlana SQ	
J9274	Kimmtrak		J7189	Novoseven RT		J1203	Pombiliti		J2998	Ryplazim		J3241	Tepezza 🔺 🚺	J7183	Wilate	
J3590	Kisunla 4		J2802	Nplate		J9204	Poteligeo		J9333	Rystiggo		J9329	Tevimbra	Q5136	Wyost	
J7190	Koate DVI		J2182	Nucala		J0885	Procrit/Epogen		J0870	Rytelo		J2356	Tezspire 🔺 🕻	<b>J</b> 0218	Xenpozyme	
J7192	Kogenate F	SAC	J7209	Nuwiq		J7194	Profilnine		J9361	Ryzneuta		J9273	Tivdak	J0897	Xgeva	
J7211	Kovaltry		J3590	Nypozi		J0256	Prolastin-C		J0491	Saphnelo		Q5133	Tofidence	J2357	Xolair	
J2507	Krystexxa		J7188	Obizur		J0897	Prolia		J9227	Sarclisa		J9033	Treanda	J7185	Xyntha	
Q2042	Kymriah		J2350	Ocrevus		Q2043	Provenge		J7352	Scenesse		J1628	Tremfya IV	<b>]</b> J9228	Yervoy	
J9047	Kyprolis		J3590	Ocrevus Zunovo		Q9997	Pyzchiva IV		Q9998	Selarsdi IV		J7181	Tretten	<b>]</b> J3590	Yesafili	
J0217	Lamzede		J3590	Omisirge		Q9996	Pyzchiva SQ		Q9998	Selarsdi SQ		J9317	Trodelvy	Q2041	Yescarta	
J0202	Lemtrada 4		J2267	Omvoh IV		J1304	Qalsody		J7212	Sevenfact		Q5135	Tyenne IV	<b>J</b> 9352	Yondelis	
J0174	Leqembi 4		J9266	Oncaspar		J1301	Radicava		J1602	Simponi_AR	IA 🗖	Q5134	Tyruko	<b>J</b> 9400	Zaltrap	
J1306	Leqvio		J9205	Onivyde		J7203	Rebinyn		J2327	Skyrizi IV		J2323	Tysabri 🔺	J0256	Zemaira	
J9119	Libtayo		J0222	Onpattro		J0896	Reblozyl		J1300	Soliris		Q5111	Udenyca 🗛 🗖	J9223	Zepzelca	
J3263	Loqtorzi		Q5112	Ontruzant	Δ	J7192	Recombinate		J1747	Spevigo		J1303	Ultomiris 🔺 🗖	Q5120	Ziextenzo	
J2778	Lucentis		J9299	Opdivo		Q5125	Releuko		J2326	Spinraza		J1823	Uplizna 🗧	<b>J</b> 3304	Zilretta	
J0221	Lumizyme		J9298	Opdualag		J1745	Remicade		J3358	Stelara IV		J2777	Vabysmo 🔺 🗖	<b>]</b> J9359	Zynlonta	
J9350	Lunsumio		J3590	Opuviz		Q5104	Renflexis		J3357	Stelara SQ		J9303	Vectibix	J9345	Zynyz	
J9999	Lymphir		J0129	Orencia		Q5106	Retacrit		Q5127	Stimufend		Q5129	Vegzelma			I
J9353	Margenza		J3590	Otulfi IV		J3590	Revcovi		J1627	Sustol		J9376	Veopoz 🗧	_		
J3397	Mepsevii*		J3590	Otulfi SQ		Q5123	Riabni		J2779	Susvimo		J1322	Vimizim 🔺	]		
J9349	Monjuvi		J0224	Oxlumo		J9312	Rituxan		J2781	Syfovre		J9056	Vivimusta			
J1437	Monoferric		J9264	paclitaxel albumin-	bound	J9311	Rituxan Hycela	Δ	90378	Synagis		J7179	Vonvendi 🔺			

The above list consist of all drugs that are in scope for the PA Program. The drugs that were previously reviewed by the Prime MDR program and will transition to MPS Prime for prior authorization are represented with a "\_\_\_\_\_". The drugs that are in scope for State of Kansas Employee Health Plan are represented with a "\_\_\_\_\_".

Other drugs may require preauthorization through Blue Cross and the above list is subject to change. Please visit <a href="https://gatewaypa.com/policydisplay/54">https://gatewaypa.com/policydisplay/54</a> for current list of in scope 8 medications.

# **Review Process**

### **Provider Responsibilities**



Ordering Provider Responsible for obtaining the prior authorization before services are provided.



Rendering Provider Responsible for ensuring that the authorization was obtained prior to services being rendered.

### **Information Needed**



### Provider

- Ordering Provider Name
- Tax ID
- Practice Address
- Office Telephone and Fax

(Same information is needed for Rendering Provider if different from Ordering Provider)



### Member

- Member Name
- Date of Birth
- Member ID Number
- Height
- Weight
- Diagnosis Code



### **Medication**

- Place of Service Code
- Requested Drug Name or HCPCS Code
- Dosage
- Frequency
- Anticipated Start Date of Treatment



## Clinical

- Clinical notes
- Pathology Reports
- Relevant Test Results

If additional information is requested by Prime, the practitioner should be prepared to upload documents on the provider portal or to fax documents to Prime HIPAA compliant fax.

#### **Determination Process Flow**

by the requestor.

# **PHARMACIST REVIEW** If additional detail is needed, the case is routed to a Prime pharmacist who will outreach to the requesting provider. INTAKE **PHYSICIAN REVIEW** In most cases, approvals can be made The case may be escalated to a Prime based on initial information provided physician, who will discuss case with

1 2

the ordering provider.

Authorizations issued by BCBSKS for dates of service before August 15<sup>th</sup>, 2025, for the medications identified as part of this program will be effective until the authorizations end date.

Claims for dates of services after the authorized end date will be denied if the provider has not obtained a successive authorization from Prime.



To continue treatment after the original authorization validity date, you must obtain an authorization from Prime prior to the expiration date.

# **Provider Portal**


## **Obtaining an Online Account**

GatewayPA.com - Prescribers directly contracted with BCBSKS may create an online account for Authorizations in 3 easy steps:

- 1. Visit our self-service online portal at <u>www.GatewayPA.com</u>
- 2. Click on New Provider Access Request under the Sign In box
- 3. Complete the form to request access

#### **Please note:**

- Authorizations for all Prime Medical Pharmacy Prior Authorizations plans may be managed under one user account. For providers who already have an established account for another Healthplan, they may email <u>provideringuiry@primetherapeutics.com</u> to request that BCBSKS be added to their account. (if applicable)
- The portal is for routine requests only.
- Urgent requests and retroactive requests must be phoned in to the Prime Operations Team at: 800-424-1713



# Resources

#### **Authorization Resources**





For routine requests and clinical policy information, visit GatewayPA.com For urgent or expedited requests call Prime at 800-424-1713 Prime has staff available 24 hours per day for urgent requests by phone (including after hours, weekends and holidays).

If you have claim, benefits, and/or eligibility questions, please call BCBSKS at 800-432-3990 Monday-Friday from 8:00AM – 4:30PM CST

# THANK YOU

Contact email: ProviderInquiry@PrimeTherapeutics.com